Risk of hip/femur fractures in patients using antipsychotics

Bone

Volumn 37, Issue 6, 2005, Pages 864-870

  Hugenholtz, Gerard W K ^a,b   Heerdink, Eibert R ^b   Van Staa, Tjeerd P ^b,d,e   Nolen, Willem A ^a,c   Egberts, Antoine C G ^b  

^a Altrecht Institute for Mental Health Care   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^d UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^e PROCTER AND GAMBLE COMPANY   (United States)

Author keywords

Antipsychotics; Femur; Fractures; Hip

Indexed keywords

ALPHA 1 ADRENERGIC RECEPTOR; AMISULPRIDE; BENPERIDOL; CHLORPROMAZINE; CLOZAPINE; FLUPENTIXOL; FLUPHENAZINE; FLUSPIRILENE; HALOPERIDOL; HISTAMINE H1 RECEPTOR; LEVOMEPROMAZINE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PERICIAZINE; PERPHENAZINE; PIMOZIDE; PIPOTIAZINE; PROMAZINE; QUETIAPINE; RISPERIDONE; SERTINDOLE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; ZOTEPINE; ZUCLOPENTHIXOL;

ADULT; AGED; ARTICLE; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; FEMUR FRACTURE; GEOGRAPHIC DISTRIBUTION; HIP FRACTURE; HUMAN; LOGISTIC REGRESSION ANALYSIS; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; RECEPTOR BLOCKING; REGISTER; RISK ASSESSMENT;

ADOLESCENT; ADULT; AGED; ANTIPSYCHOTIC AGENTS; CASE-CONTROL STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FEMORAL FRACTURES; GREAT BRITAIN; HIP FRACTURES; HUMANS; MALE; MIDDLE AGED; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, HISTAMINE H1; RISK;

EID: 28844479756     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2005.07.005     Document Type: Article

References (40)

1. Anonymous Anatomical Therapeutical Chemical (ATC) Classification index 2004 WHO Collaboration Centre for Drugs Statistics Methodology Oslo
2. Anonymous ATC index with DDDs 2004 WHO Collaborating Centre for Drug Statistics Methodology Oslo January 2002
3. P.C. Baastrup, C. Christiansen, and I. Transbol Calcium metabolism in schizophrenic patients on long-term neuroleptic therapy Neuropsychobiology 6 1980 56 59
4. S. Bazire Psychotropic drug directory: the mental health professionals' handbook 2003/04 Quay Books Wilts [UK] West Orange, NJ
5. D. Becker, O. Liver, R. Mester, M. Rapoport, A. Weizman, and M. Weiss Risperidone, but not olanzapine, decreases bone mineral density in female premenopausal schizophrenia patients J. Clin. Psychiatry 64 2003 761 766
6. G.M. Clifford, and R.D. Farmer Medical therapy for benign prostatic hyperplasia: a review of the literature Eur. Urol. 38 2000 2 19
7. R.G. Cumming, and R.J. Klineberg Psychotropics, thiazide diuretics and hip fractures in the elderly Med. J. Aust. 158 1993 414 417
8. R.G. Cumming, and D.G. Le Couteur Benzodiazepines and risk of hip fractures in older people: a review of the evidence CNS Drugs 17 2003 825 837
9. R.G. Cumming, M.C. Nevitt, and S.R. Cummings Epidemiology of hip fractures Epidemiol. Rev. 19 1997 244 257
10. J.M. Davis, P.G. Janicak, Z. Wang, R.D. Gibbons, and R.P. Sharma The efficacy of psychotropic drugs: implications for power analysis Psychopharmacol. Bull. 28 1992 151 155
11. S.L. Greenspan, D.S. Oppenheim, and A. Klibanski Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism Ann. Intern. Med. 110 1989 526 531
12. U. Halbreich, N. Rojansky, S. Palter, M. Hreshchyshyn, J. Kreeger, and Y. Bakhai Decreased bone mineral density in medicated psychiatric patients Psychosom. Med. 57 1995 485 491
13. R.M. Herings, B.H. Stricker, A. de Boer, A. Bakker, and F. Sturmans Benzodiazepines and the risk of falling leading to femur fractures. Dosage more important than elimination half-life Arch. Intern. Med. 155 1995 1801 1807
14. J.L. Hopper, and E. Seeman The bone density of female twins discordant for tobacco use N. Engl. J. Med. 330 1994 387 392
15. R. Hubbard, P. Farrington, C. Smith, L. Smeeth, and A. Tattersfield Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture Am. J. Epidemiol. 158 2003 77 84
16. S.S. Jick, J.A. Kaye, C. Vasilakis-Scaramozza, L.A. Garcia Rodriguez, A. Ruigomez, and C.R. Meier Validity of the general practice research database Pharmacotherapy 23 2003 686 689
17. B.J. Kinon, and J.A. Lieberman Mechanisms of action of atypical antipsychotic drugs: a critical analysis Psychopharmacology (Berlin) 124 1996 2 34
18. A. Kuruvilla, G. Srikrishna, J. Peedicayil, K. Kuruvilla, and A.S. Kanagasabapathy A study on serum prolactin levels in schizophrenia: correlation with positive and negative symptoms Int. Clin. Psychopharmacol. 8 1993 177 179
19. R.M. Leipzig, R.G. Cumming, and M.E. Tinetti Drugs and falls in older people: a systematic review and meta-analysis: I. Psychotropic drugs J. Am. Geriatr. Soc. 47 1999 30 39
20. A.J. Man in't Veld Symptomatic BPH and hypertension: does comorbidity affect quality of life? Eur. Urol. 34 Suppl 2 1998 29 36 [discussion 47]
21. A.M. Meaney, S. Smith, O.D. Howes, M. O'Brien, R.M. Murray, and V. O'Keane Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia Br. J. Psychiatry 184 2004 503 508
22. K.K. Miller, and A. Klibanski Clinical review 106: amenorrheic bone loss J. Clin. Endocrinol. Metab. 84 1999 1775 1783
23. G.R. Mundy Osteopenia Dis. Mon. 33 1987 537 600
24. G.R. Mundy, D. Chen, M. Zhao, S. Dallas, C. Xu, and S. Harris Growth regulatory factors and bone Rev. Endocr. Metab. Disord. 2 2001 105 115
25. U. Naidoo, D.C. Goff, and A. Klibanski Hyperprolactinemia and bone mineral density: the potential impact of antipsychotic agents Psychoneuroendocrinology 2 Suppl 2 2003 97 108
26. I. Nazareth, M. King, A. Haines, L. Rangel, and S. Myers Accuracy of diagnosis of psychosis on general practice computer system BMJ 307 1993 32 34
27. P. Peris, A. Pares, N. Guanabens, F. Pons, M.J. Martinez de Osaba, and J. Caballeria Reduced spinal and femoral bone mass and deranged bone mineral metabolism in chronic alcoholics Alcohol Alcohol. 27 1992 619 625
28. R.G. Petty Prolactin and antipsychotic medications: mechanism of action Schizophr. Res. 35 1999 S67 S73 [Suppl]
29. W.A. Ray, M.R. Griffin, and W. Downey Benzodiazepines of long and short elimination half-life and the risk of hip fracture JAMA 262 1989 3303 3307
30. W.A. Ray, M.R. Griffin, W. Schaffner, D.K. Baugh, and L.J. Melton III Psychotropic drug use and the risk of hip fracture N. Engl. J. Med. 316 1987 363 369
31. J.A. Schlechte, B. Sherman, and R. Martin Bone density in amenorrheic women with and without hyperprolactinemia J. Clin. Endocrinol. Metab. 56 1983 1120 1123
32. I. Sernbo, A. Hansson, and O. Johnell Drug consumption in patients with hip fractures compared with controls Compr. Gerontol., A 1 1987 93 96
33. P.C. Souverein, T.P. Van Staa, A.C. Egberts, J.J. De la Rosette, C. Cooper, and H.G. Leufkens Use of alpha-blockers and the risk of hip/femur fractures J. Intern. Med. 254 2003 548 554
34. T.P. van Staa, L. Abenhaim, C. Cooper, B. Begaud, B. Zhang, and H.G. Leufkens The use of a large pharmaco-epidemiological database to study exposure to oral corticosteroids and risk of fractures: validation of study population and results Pharmacoepidemiol. Drug Saf. 9 2000 359 366
35. T.P. van Staa, H.G. Leufkens, and C. Cooper Utility of medical and drug history in fracture risk prediction among men and women Bone 31 2002 508 514
36. T. Walley, and A. Mantgani The UK general practice research database Lancet 350 1997 1097 1099
37. P.S. Wang, R.L. Bohn, R.J. Glynn, H. Mogun, and J. Avorn Hazardous benzodiazepine regimens in the elderly: effects of half-life, dosage, and duration on risk of hip fracture Am. J. Psychiatry 158 2001 892 898
38. P.S. Wang, R.L. Bohn, R.J. Glynn, H. Mogun, and J. Avorn Zolpidem use and hip fractures in older people J. Am. Geriatr. Soc. 49 2001 1685 1690
39. A. Wieck, and P.M. Haddad Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review Br. J. Psychiatry 182 2003 199 204
40. T. Youm, K.J. Koval, F.J. Kummer, and J.D. Zuckerman Do all hip fractures result from a fall? Am. J. Orthop. 28 1999 190 194